NASDAQ: INCY

Incyte (INCY) Stock Analysis & Forecast

Nov 13 close

$120.97−0.73 (−0.6%)

Gekko Brief

AI summaryNov 9 close

Incyte raised its full-year 2026 sales guidance to a range of $5,210 million to $5,300 million after third-quarter revenue rose 14% to $1.56 billion, with growth in dermatology and oncology reducing reliance on Jakafi. The company also reported a net loss of $784.8 million for the quarter alongside the guidance increase. Separately, Incyte is advancing two experimental cancer treatments, INCB161734 and INCA33890, into late-stage trials for pancreatic and colorectal cancers, following encouraging early-stage data presented at the 2026 ESMO Congress. H.C. Wainwright maintained a Buy rating on the stock with a $152.00 price target.

Shares closed at $121.89, up 1.9%, sitting above both the 50-day average of $119.57 and the 200-day average of $108.53, with the 50-day above the 200-day. The GekkoIndex reads 51.8, placing the stock in the Neutral zone. Price sits within 0.2% of Gekko Fair Value, which stands at $122.09.

The next earnings report is scheduled for 9 February 2027, 86 days away, placing it outside a typical 20-trading-day holding window. Over the last 90 days, Congress recorded 1 buy and 0 sells. Seasonality from this point in the calendar shows the next 20 trading days averaging -1.2% over 5 years, with gains in 3 of those years. Analyst consensus across 21 firms stands at 10 buy and 11 hold ratings, with a consensus target of $130.92.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Incyte price vs fair value

$120.97$118.98Nov ’25May ’26Nov ’26
Close $120.97200-day averageGekko Fair Value $118.98

Incyte quick facts

Market cap
$24.66B
P/E ratio
62.1
Forward P/E
13.7
EPS, TTM
$1.96
Revenue, TTM
$6.01B
Profit margin
6.7%
Dividend yield
—
Beta
0.78
Volume
950,394 avg 1.73M
1-year return
+11.7%
Typical daily move
±3.7%
Typical 20-day move
±5.4%
50-day average
$119.18
200-day average
$108.92
Next earnings
Feb 9 before open
Shares outstanding
203.8M
52-week range
$89.25$132.60

Incyte swing-trade checklist

Incyte scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive2 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $120.97 is above the 50-day ($119.18) and 200-day ($108.92) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    53.8, Neutral

    Reading 53.8 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    1.7% above

    Price is within 5% of Gekko Fair Value (1.7% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: Congress 1 buy / 0 sales.

    See smart money
  • Earnings risksupportive

    Reports in 86 days

    Next report Feb 9, 2027, 86 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +2.6% on average

    From this point in the calendar, the next 20 trading days averaged +2.6% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Incyte stock chart and price history

Incyte closed at $120.97 on Nov 13, 2026, +11.7% over the past year, inside a 52-week range of $89.25 to $132.60.

Close50-day average200-day averageVolume
Incyte share price, past year, with 50-day and 200-day moving averages and volume$80$100DecJan 2026FebMarAprMayJunJulAugSepOctNov120.97

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+6.8%
3 months
−2.0%
6 months
+26.9%
1 year
+11.7%
The full INCY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open INCY in Gekko

Follow Incyte through every session

Put INCY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track INCY in GekkoFree for 7 days. No credit card required.

About Incyte

Incyte develops and sells medicines it discovers and researches itself, focusing on treatments for cancers and blood disorders. Its marketed products include Jakafi, used for myelofibrosis and polycythemia vera, Pemazyre, aimed at cancers driven by a specific enzyme abnormality, and Iclusig, prescribed for certain forms of leukemia. These approved therapies form the core of what the company is recognized for in the market today.

Beyond its current drugs, Incyte runs a pipeline of experimental treatments in various stages of clinical testing, covering conditions such as graft-versus-host disease, bladder cancer, lymphoma, endometrial cancer, and lung cancer, among others. The company works with a range of outside partners, including Novartis, Eli Lilly, and Agenus, and participates in joint clinical studies with firms such as MorphoSys and Xencor to test combination treatments for lymphoma patients. Its business relies on advancing both marketed drugs and this broader research pipeline through internal work and collaboration.

Incyte was founded in 1991 and is headquartered in Wilmington, Delaware. Its shares are listed on the NASDAQ under the ticker INCY.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
incyte.com

Incyte GekkoIndex: the smart money zone

Incyte’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.8, in the Neutral zone, up 0.3 points over five sessions.

010053.8Neutral

Up 0.3 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying47+0.2%+1.1%+3.2%+8.4%
Accumulation176+1.1%+1.2%+0.8%+4.4%
Neutral (current zone)419+0.5%+1.4%+3.2%+7.4%
Distribution530.0%−0.1%0.0%+3.5%
Selling7Too few readings yet

Average INCY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the INCY price, zone by zone.Track INCY in Gekko

Is Incyte stock overvalued? Gekko Fair Value

Incyte trades 1.7% above Gekko Fair Value of $118.98, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Incyte shares are worth, recalculated every trading day.

$118.98

Gekko Fair Value, Nov 14, 2026

1.7% above fair value · About fair value

At the end of Aug 2026 the price was 1.1% above the estimate.

Gekko Fair ValueShare price, month end
$119$121Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open INCY in Gekko

Incyte insider and Congress trading

No open-market insider purchases were filed for Incyte, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for INCY in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every INCY insider filing, plotted on the chart in Gekko.Open INCY in Gekko

Congress trades last 90 days

1trade disclosed: 1 purchase and 0 sales.

MemberTypeAmountDisclosed
Ro Khanna
House, CA, purchase
Purchase$1,001 - $15,000Oct 9
traded Sep 4

From congressional disclosures, which report amounts as ranges.

Buybacks

Incyte has been buying back its own shares.

Bought back, quarter ended Mar 31, 2026
$6.89M
As a share of market cap
0.03%

From company filings.

Incyte earnings: next date and track record

Incyte reports on Feb 9, 2027, before the open (86 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±7.7%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+12.5%Oct ’24−10.5%Feb ’25+5.3%Apr ’25+10.5%Jul ’25−3.1%Oct ’25−9.3%Feb ’26+3.5%Apr ’26+6.9%Jul ’26

Last earnings call, Jul 28, 2026 AI summary

What they said
Incyte reported Q2 2026 total revenue of $1.67 billion, up 38% YoY, with total net sales of $1.49 billion (+40% YoY), though excluding a one-time CMS settlement benefit, net sales grew 17%. Jakafi sales reached $817 million (+7% YoY) with 9% prescription demand growth. Key milestones include Jakafi XR launch ($10M Q2 sales), positive CHMP opinion for Opzelura, and acquisition of latarcibart (Phase III, von Willebrand disease) via the Vega transaction.
Guidance
Jakafi XR sales expected to reach $40-50 million in near term as formulary coverage targets 50-70% by year-end. Core business excluding Jakafi on track for $3-4 billion in net sales by 2030. Povorcitinib and Monjuvi regulatory approvals and launches anticipated through early 2027.
ReportedEPSSurpriseRevenueSurpriseMove
Jul 28, 2026$2.80
est $1.76
+59.1%$1.67B
est $1.50B
+11.3%+6.9%
Apr 28, 2026$1.81
est $1.34
+35.1%$1.27B
est $1.22B
+4.7%+3.5%
Feb 10, 2026$1.80
est $1.90
−5.3%$1.51B
est $1.35B
+11.2%−9.3%
Oct 28, 2025$2.26
est $1.66
+36.1%$1.37B
est $1.35B
+0.9%−3.1%
Jul 29, 2025$1.57
est $1.39
+12.9%$1.22B
est $1.26B
−3.3%+10.5%
Apr 29, 2025$1.16
est $1.01
+14.9%$1.05B
est $1.15B
−8.7%+5.3%
Feb 10, 2025$1.43
est $1.55
−7.7%$1.18B
est $1.00B
+17.3%−10.5%
Oct 29, 2024$0.54
est $0.79
−31.6%$1.14B
est $1.14B
−0.5%+12.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Incyte stock forecast and analyst price targets

Analysts’ average 12-month price target for Incyte is $131.50, +8.7% from the last close, from 21 firms rating the stock in the last 90 days.

$131.50consensus 12-month target, +8.7% from the last close
Low $108High $157
Buy10
Hold11
Sell0

Each firm’s latest rating in the last 90 days: 21 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 5Leerink PartnersBuy, maintained$150+24.0%
Nov 5Canaccord GenuityBuy, maintained$152+25.7%
Nov 5H.C. WainwrightBuy, maintained$152+25.7%
Nov 2H.C. WainwrightBuy, reiterated$152+25.7%
Nov 2Bank of America SecuritiesBuy, maintained$143+18.2%
+3.2%average 20-day move after past Neutral readings
+2.6%average move over the next 20 trading days in the last 5 years
±3.7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Incyte seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Incyte averaged +2.6% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

+5.2%2021+7.5%2022+17.6%2023−11.8%2024−5.3%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−3.5%1 of 5
Next 10 trading days−1.1%2 of 5
Next 15 trading days−0.6%3 of 5
Next 20 trading days+2.6%3 of 5
Next 30 trading days+2.4%3 of 5

For scale, INCY’s typical 20-trading-day move in either direction is about 5.4%.

Incyte market cap and key statistics

Incyte’s market cap is $24.66B, with a P/E ratio of 62.1 and revenue of $6.01B over the last twelve months.

Valuation

Market cap
$24.66B
P/E ratio
62.1
Forward P/E
13.7
EPS, TTM
$1.96
Gekko Fair Value
$118.98

Trading

Volume
950,394
Avg volume, 20 days
1.73M
52-week high
$132.60
52-week low
$89.25
Shares outstanding
203.8M

Financials

Revenue, TTM
$6.01B
Profit margin
6.7%
Return on equity
7.8%
Quarterly earnings growth, YoY
+37.7%

Risk and income

Beta
0.78
Typical daily move
±3.7%
Typical 20-day move
±5.4%

Incyte peers

Incyte’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Incyte stock FAQ

What is Incyte’s market cap?

Incyte’s market cap is $24.66B at the Nov 13, 2026 close of $120.97, with 203.8M shares outstanding. The shares trade on a P/E ratio of 62.1.

What is the Incyte stock forecast?

The consensus analyst 12-month price target for Incyte is $131.50, +8.7% from the last close. Of the 21 firms that rated the stock in the last 90 days, 10 rate it a buy, 11 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Incyte stock overvalued or undervalued?

On Gekko’s estimate Incyte is about fair value: the Nov 13, 2026 close of $120.97 is 1.7% above Gekko Fair Value of $118.98. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Incyte report earnings next?

Incyte is expected to report on Feb 9, 2027, before the market opens (86 days away). Analysts expect earnings of $1.90 per share on revenue of $1.56B. Incyte beat the earnings estimate in 5 of its last 8 reports, moving 7.7% on average across the report.

What is Incyte’s 52-week high and low?

Incyte’s 52-week high is $132.60 and its 52-week low is $89.25; it closed at $120.97 on Nov 13, 2026, +11.7% over the past year.

Is Incyte stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Incyte the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.